Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the safety and tolerability of a single
intradermal administration of RXI-109 at small surgical incisions in the abdominal skin that
will later be removed during an elective abdominoplasty. The effect of RXI-109 versus placebo
on scarring at these incision sites will be evaluated visually and histologically.